{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:48:29Z","timestamp":1790588909334,"version":"4.1.0"},"reference-count":23,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>Hu7691 represents a novel Pan-Akt kinase inhibitor, demonstrating excellent selectivity towards non-AGC kinase families and pronounced inhibitory effects on the proliferation of multiple tumor cell lines. However, there is currently a notable absence of in vivo toxicological research evidence concerning Hu7691. This study represents the first investigation into the 14-day repeated-dose toxicity of Hu7691 in male and female Sprague Dawley (SD) rats. Male rats were administered daily doses of 12.5, 50, 100, and 150 mg\/kg\/day, while female rats received doses of 12.5, 25, 50, and 75 mg\/kg\/day for 14 consecutive days. Hematological assessments, organ weights, and histopathological examinations revealed corresponding alterations, suggesting potential target organs for toxicity including the spleen, thymus, and gastrointestinal tract. It is worth noting that the test substance may also impact the liver, kidneys, heart, and ovaries. The No Observed Effect Level (NOAEL) was determined to be no greater than 12.5 mg\/kg\/day. Based on the observed gender-related toxicity differences in preliminary trials, it is recommended that the high dose reference dose for male animals in formal experiments should not be less than 100 mg\/kg\/day, while for female animals, it should be less than 50 mg\/kg\/day.<\/jats:p>","DOI":"10.3390\/toxics11110880","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:50:18Z","timestamp":1698407418000},"page":"880","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, following Oral Administration in Rats"],"prefix":"10.3390","volume":"11","author":[{"given":"Renhua","family":"Gai","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Heilongjiang Key Laboratory for Animal and Comparative Medicine, Northeast Agricultural University, Harbin 150030, China"},{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chi","sequence":"additional","affiliation":[{"name":"Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxing","family":"Li","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Heilongjiang Key Laboratory for Animal and Comparative Medicine, Northeast Agricultural University, Harbin 150030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer ge-nome projects","volume":"464","author":"Anderson","year":"2010","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1021\/jm301024w","article-title":"Dis-covery and Preclinical Pharmacology of a Selective ATPCompetitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors","volume":"55","author":"Blake","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/1568026620666200224101808","article-title":"Akt Pathway Inhibitors","volume":"20","author":"Uko","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI95802","article-title":"Hippo-mediated suppression of IRS2\/AKT signaling prevents hepatic steatosis and liver cancer","volume":"128","author":"Jeong","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.3892\/ol.2017.5894","article-title":"Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K\/AKT\/mTOR signalling pathway","volume":"13","author":"Lin","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s10637-021-01085-7","article-title":"Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase\/v-akt murine thymoma viral oncogene homolog gene mutations","volume":"39","author":"Lee","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Roudsari, N.M., Lashgari, N.-A., Momtaz, S., Abaft, S., Safaiepour, P., Narimisa, K., Jackson, G., Bishayee, A., Rezaei, N., and Bishayee, A. (2021). Inhibitors of the PI3K\/Akt\/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081195"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ghoneum, A., and Said, N. (2019). PI3K-AKT-mTOR and NF_B Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers, 11.","DOI":"10.3390\/cancers11070949"},{"key":"ref_11","first-page":"185","article-title":"The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts","volume":"1870","author":"McKenna","year":"2018","journal-title":"BBA\u2014Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cca.2014.12.041","article-title":"PI3K\/Akt signaling in osteosarcoma","volume":"444","author":"Zhang","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14737140.7.6.863","article-title":"Targeting the PI3K-Akt pathway in kidney cancer","volume":"7","author":"Park","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.oraloncology.2014.11.012","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in squamous cell carcinomaof the head and neck","volume":"51","author":"Simpson","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S1097-2765(02)00550-6","article-title":"Molecular Mechanism for the Regulation of Protein Kinase B\/Akt by Hydrophobic Motif Phosphorylation","volume":"9","author":"Yang","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_16","first-page":"E3940","article-title":"Conformational sampling of membranes by Akt controls its activation and inactiva-tion","volume":"115","author":"Luci","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.apsb.2023.01.024","article-title":"AKT inhibitor Hu7691 in-duces differentiation of neuroblastoma cells","volume":"13","author":"Bing","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ame2.12041","article-title":"Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the Animal House, Faculty of Medicine, University of Colombo, Sri Lanka","volume":"1","author":"Delwatta","year":"2018","journal-title":"Animal Model Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12163\u221212180","DOI":"10.1021\/acs.jmedchem.1c00815","article-title":"Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutane-ous Toxicity","volume":"64","author":"Che","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/01480545.2022.2029880","article-title":"Inhibition of methotrexate induced toxicity in the adult rat spleen by adalimumab","volume":"2","author":"Bahceci","year":"2023","journal-title":"Drug Chem. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/0192623319867053","article-title":"Nonproliferative and Proliferative Lesions of the Rat and Mouse Hematolymphoid System","volume":"47","author":"Elmore","year":"2019","journal-title":"J. Toxicol. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1293\/tox.29.1S","article-title":"Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse","volume":"29","author":"Nolte","year":"2016","journal-title":"J. Toxicol. Pathol."}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/11\/11\/880\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:33Z","timestamp":1760130753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/11\/11\/880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["toxics11110880"],"URL":"https:\/\/doi.org\/10.3390\/toxics11110880","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}